Systems-pharmacology dissection of a drug synergy in imatinib-resistant CML.

@article{Winter2012SystemspharmacologyDO,
  title={Systems-pharmacology dissection of a drug synergy in imatinib-resistant CML.},
  author={Georg E Winter and Uwe Rix and Scott M. Carlson and Karoline V. Gleixner and Florian Grebien and Manuela Gridling and Andr{\'e} C. Mueller and Florian P. Breitwieser and Martin Bilban and Jacques Colinge and Peter Valent and Keiryn L. Bennett and Forest M. White and Giulio Superti-Furga},
  journal={Nature chemical biology},
  year={2012},
  volume={8 11},
  pages={905-912}
}
Occurrence of the BCR-ABL(T315I) gatekeeper mutation is among the most pressing challenges in the therapy of chronic myeloid leukemia (CML). Several BCR-ABL inhibitors have multiple targets and pleiotropic effects that could be exploited for their synergistic potential. Testing combinations of such kinase inhibitors identified a strong synergy between danusertib and bosutinib that exclusively affected CML cells harboring BCR-ABL(T315I). To elucidate the underlying mechanisms, we applied a… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 35 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 44 references

Safety and efficacy of bosutinib (SKI-606) in chronic phase Philadelphia chromosome-positive chronic myeloid leukemia patients with resistance or intolerance to imatinib

JE Cortes
2011

Selective inhibition of BET bromodomains

P Filippakopoulos
Nature • 2010

Similar Papers

Loading similar papers…